Arvinas, Inc.

Arvinas, Inc.

We are Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics. Our pipeline of proteolysis targeting chimeras, or PROTAC® protein degraders, are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Breast Cancer, Genitourinary Cancer, Biotechnology, Clinical Research, Clinical Trials

Yes